Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine + Low-Dose TBI for AML Transplant
NCT01252667Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jan 2011
- Primary completion
- Jan 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of clofarabine in acute myeloid leukemia (AML) (6 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Number of Participants With Dose Limiting Toxicities and Number of Participants With Relapsed Disease. Started Jan 2011; status: completed.
02
Drugs
clofarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01252667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01252667.